Berenberg Bank Analysts Give Gilead Sciences, Inc. (GILD) a $96.00 Price Target
Berenberg Bank set a $96.00 price target on Gilead Sciences, Inc. (NASDAQ:GILD) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms have also recently commented on GILD. Needham & Company LLC restated a hold rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr upgraded Gilead Sciences from a hold rating to a buy rating and set a $89.27 target price for the company in a research note on Wednesday, September 6th. Morgan Stanley reiterated an equal weight rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Maxim Group reiterated a hold rating on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, ValuEngine cut Gilead Sciences from a strong-buy rating to a buy rating in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $85.64.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.47% during trading on Thursday, hitting $81.21. The stock had a trading volume of 9,188,325 shares. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The firm has a 50 day moving average price of $82.63 and a 200-day moving average price of $72.65. The stock has a market capitalization of $106.05 billion, a price-to-earnings ratio of 8.82 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.08 EPS. On average, equities research analysts forecast that Gilead Sciences will post $8.74 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.56%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is presently 22.58%.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,338,919 in the last three months. 1.30% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Seizert Capital Partners LLC lifted its position in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after acquiring an additional 27,547 shares in the last quarter. Linscomb & Williams Inc. lifted its position in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 154 shares in the last quarter. Investment Centers of America Inc. lifted its position in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after acquiring an additional 1,958 shares in the last quarter. HealthInvest Partners AB lifted its position in shares of Gilead Sciences by 3.5% in the first quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock valued at $7,947,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Capital Asset Advisory Services LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at about $875,000. Institutional investors and hedge funds own 73.97% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.